Prodhan P, Gossett J M, Rycus P T, Gupta P
Division of Pediatric Cardiology, University of Arkansas Medical Sciences, Little Rock, Arkansas, USA Division of Critical Care, University of Arkansas Medical Sciences, Little Rock, Arkansas, USA
Division of Biostatistics, Department of Pediatrics, University of Arkansas Medical Sciences, Little Rock, Arkansas, USA.
Perfusion. 2015 Nov;30(8):660-5. doi: 10.1177/0267659115578945. Epub 2015 Mar 20.
The study objective was to evaluate outcomes among children with del22q11 (DiGeorge) syndrome supported on ECMO for heart disease. The ELSO registry database was queried to include all children <18 years undergoing heart surgery for either common atrio-ventricular canal, tetralogy of Fallot, truncus arteriosus or transposition of the great vessels and interrupted aortic arch and requiring ECMO, from 1998-2011. The outcomes evaluated included mortality, ECMO duration and length of hospital stay in patients with del22q11 syndrome and with no del22q11 syndrome. Eighty-eight ECMO runs occurred in children with del22q11 syndrome while 2694 ECMO runs occurred in children without del22q11 syndrome. For patients with heart defects receiving ECMO, del22q11 syndrome did not confer a significant mortality risk or an increased risk of infectious complications before or while on ECMO support. Neither the duration of ECMO nor mechanical ventilation prior to ECMO deployment were prolonged in patients with del22q11 syndrome compared to the controls.
本研究的目的是评估患有22q11缺失（迪乔治）综合征的儿童在接受体外膜肺氧合（ECMO）支持治疗心脏病后的预后情况。查询体外生命支持组织（ELSO）登记数据库，纳入1998年至2011年间所有年龄小于18岁、因共同房室通道、法洛四联症、动脉干、大动脉转位或主动脉弓中断而接受心脏手术且需要ECMO支持的儿童。评估的预后指标包括22q11综合征患儿和非22q11综合征患儿的死亡率、ECMO持续时间和住院时间。22q11综合征患儿进行了88次ECMO治疗，而非22q11综合征患儿进行了2694次ECMO治疗。对于接受ECMO治疗的心脏缺陷患者，22q11综合征在ECMO支持前或支持期间并未带来显著的死亡风险或感染并发症风险增加。与对照组相比，22q11综合征患者在ECMO治疗前的ECMO持续时间和机械通气时间均未延长。
